Last reviewed · How we verify
JW0108 + C2407
JW0108 + C2407 is a combination therapy designed to enhance anti-tumor immunity through dual immunological mechanisms.
JW0108 + C2407 is a combination therapy designed to enhance anti-tumor immunity through dual immunological mechanisms. Used for Solid tumors (specific indication under investigation in phase 3).
At a glance
| Generic name | JW0108 + C2407 |
|---|---|
| Sponsor | JW Pharmaceutical |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific details on this combination are limited in public literature, JW Pharmaceutical's pipeline suggests this may involve complementary immune checkpoint modulation or T-cell activation pathways. The combination approach is typical of phase 3 oncology programs aiming to improve response rates over monotherapy.
Approved indications
- Solid tumors (specific indication under investigation in phase 3)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JW0108 + C2407 CI brief — competitive landscape report
- JW0108 + C2407 updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI